NELL-1 Signaling in Osteogenesis and Cranial Development

NELL-1 is a secreted, multimodular glycoprotein that plays a pivotal role in intramembranous ossification and the maintenance of cranial suture patency. Originally identified through its up-regulation in prematurely fused coronal sutures, NELL-1 modulates the balance between osteoblast-driven bone formation and osteoclast-mediated resorption. Mechanistically, NELL-1 engages integrin β1 at the cell surface to trigger downstream Wnt/β-catenin signalling, thereby promoting osteogenic differentiation while inhibiting osteoclast activity. Genetic ablation of Nell-1 in animal models leads to undermineralised calvaria and age-related bone loss, whereas overexpression causes craniosynostotic phenotypes. Beyond its developmental functions, NELL-1 has emerged as a promising therapeutic agent for bone regeneration, with both systemic and local delivery demonstrating efficacy in restoring bone mass and accelerating fracture healing. Recent advances have also explored its interplay with key transcriptional regulators such as Runx2 and Osterix, as well as cross-talk with adipogenic pathways governed by PPARγ, highlighting NELL-1’s integrative role in skeletal homeostasis and craniofacial morphogenesis.

Research from Nature Portfolio

Recent studies have confirmed NELL-1’s capacity to restore bone density in osteoporotic settings by binding integrin β1 and activating canonical Wnt/β-catenin signalling. In murine models of gonadectomy-induced osteoporosis, systemic administration of recombinant NELL-1 rebalanced osteoblast-to-osteoclast ratios and improved bone mineral density. Translation to a large-animal spinal model further demonstrated that local NELL-1 delivery stimulates robust new bone formation in osteoporotic environments. These findings validate NELL-1 as both an anabolic and antiresorptive agent, offering a dual-mechanism strategy for the treatment of skeletal fragility and cranial bone defects.

NELL-1 Signaling in Osteogenesis and Cranial Development publication trend

The graph below shows the total number of articles in nell-1 signaling in osteogenesis and cranial development across all publications each year (not limited to Nature Index journals).

Technical terms

NELL-1: A secreted glycoprotein involved in osteoinduction and cranial suture regulation.

Osteoblast: A bone-forming cell responsible for deposition of mineralised matrix.

Osteoclast: A bone-resorbing cell that degrades mineralised matrix.

Wnt/β-catenin signalling: A pathway critical for osteoblast differentiation and skeletal development.

Integrin β1: A cell-surface receptor that mediates extracellular matrix interactions and transduces signals for osteogenesis.

Runx2: A master transcription factor essential for osteoblast lineage commitment.

PPARγ: A nuclear receptor that drives adipogenesis and can antagonise osteogenic differentiation.

References

1. Human NELL‐1 Expressed in Unilateral Coronal Synostosis. Journal of Bone and Mineral Research (1999).
2. NELL-1 in the treatment of osteoporotic bone loss. Nature Communications (2015).
3. Runx2 and Nell-1 in dental follicle progenitor cells regulate bone remodeling and tooth eruption. Stem Cell Research & Therapy (2022).
4. Genetic and pharmacologic suppression of PPARγ enhances NELL-1-stimulated bone regeneration. Biomaterials (2022).
5. Activation of Nell-1 in BMSC Sheet Promotes Implant Osseointegration Through Regulating Runx2/Osterix Axis. Frontiers in Cell and Developmental Biology (2020).
6. NELL-1, an Osteoinductive Factor, Is a Direct Transcriptional Target of Osterix. PLOS ONE (2011).